Qiagen (NYSE:QGEN) Given Average Recommendation of “Hold” by Brokerages

Qiagen (NYSE:QGEN) has been assigned a consensus recommendation of “Hold” from the nine ratings firms that are covering the firm, Marketbeat.com reports. Five research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $48.78.

Several research analysts recently commented on QGEN shares. Jefferies Financial Group restated a “buy” rating and issued a $52.50 price target (up previously from $40.83) on shares of Qiagen in a report on Tuesday, December 10th. Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research report on Thursday, October 17th. Morgan Stanley restated an “equal weight” rating and set a $46.67 target price (down previously from $48.61) on shares of Qiagen in a report on Monday, January 6th. UBS Group lowered their price target on Qiagen from $50.00 to $48.00 and set a “neutral” rating for the company in a report on Friday. Finally, HSBC cut Qiagen from a “buy” rating to a “hold” rating and set a $47.64 price objective on the stock. in a research note on Thursday, October 17th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Massmutual Trust Co. FSB ADV boosted its stake in Qiagen by 39.8% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock valued at $39,000 after acquiring an additional 243 shares during the last quarter. Geneos Wealth Management Inc. raised its stake in Qiagen by 41.5% during the fourth quarter. Geneos Wealth Management Inc. now owns 856 shares of the company’s stock valued at $38,000 after buying an additional 251 shares in the last quarter. CWM LLC lifted its holdings in Qiagen by 11.5% during the 3rd quarter. CWM LLC now owns 2,792 shares of the company’s stock worth $127,000 after buying an additional 287 shares during the last quarter. Zurich Insurance Group Ltd FI grew its position in shares of Qiagen by 5.7% in the 3rd quarter. Zurich Insurance Group Ltd FI now owns 5,291 shares of the company’s stock worth $239,000 after acquiring an additional 287 shares in the last quarter. Finally, National Bank of Canada FI raised its position in shares of Qiagen by 1.2% during the 3rd quarter. National Bank of Canada FI now owns 25,636 shares of the company’s stock valued at $1,155,000 after acquiring an additional 308 shares in the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Stock Down 2.6 %

Shares of QGEN opened at $41.34 on Monday. The firm has a market cap of $9.17 billion, a PE ratio of 115.09, a price-to-earnings-growth ratio of 3.29 and a beta of 0.36. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39. The company’s fifty day moving average is $43.78 and its two-hundred day moving average is $43.29. Qiagen has a fifty-two week low of $40.15 and a fifty-two week high of $49.30.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.60 by $0.01. Qiagen had a return on equity of 13.97% and a net margin of 4.23%. Analysts forecast that Qiagen will post 2.28 earnings per share for the current year.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.